Late-onset MS is associated with an increased rate of reaching disability milestones.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 18 11 2020
accepted: 22 02 2021
revised: 20 02 2021
pubmed: 8 3 2021
medline: 14 8 2021
entrez: 7 3 2021
Statut: ppublish

Résumé

To describe patient characteristics and assess the risk of disability worsening in patients of different age groups with focus on late-onset multiple sclerosis (LOMS) defined as disease onset after the age of 50 years. The nationwide population-based Danish Multiple Sclerosis Registry served as data source. We described baseline characteristics and analyzed rates of reaching Expanded Disability Status Scale (EDSS) milestones. We identified 28,232 patients with MS with a known year of clinical onset, of which 2661 had LOMS. The LOMS group had a higher proportion of males and patients with primary progressive disease course, and they were less likely to receive disease-modifying therapy. The initial rate of reaching EDSS milestone 6 after diagnosis was higher in LOMS [hazard ratio (HR) 1.53; 95% confidence interval (CI) 1.14-2.06]; however, when assessing the risk of reaching EDSS 6 according to age, the HR was significantly lower for the LOMS group (HR 0.307; 95% CI 0.221-0.426). The clinical characteristics and treatment approaches for patients with LOMS differ from their younger counterparts. Following diagnosis, patients with LOMS initially have an increased rate of reaching EDSS score 6; however, the risk of reaching EDSS score 6 at any given age is higher in patients with non-LOMS.

Identifiants

pubmed: 33677675
doi: 10.1007/s00415-021-10490-0
pii: 10.1007/s00415-021-10490-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3352-3360

Informations de copyright

© 2021. Springer-Verlag GmbH, DE part of Springer Nature.

Références

Koch-Henriksen N, Thygesen LC, Stenager E et al (2018) Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology 90:e1954–e1963. https://doi.org/10.1212/WNL.0000000000005612
doi: 10.1212/WNL.0000000000005612 pubmed: 29720546
D’Amico E, Patti F, Zanghì A et al (2018) Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. Eur J Neurol 25:1425–1431. https://doi.org/10.1111/ene.13745
doi: 10.1111/ene.13745 pubmed: 29956427
Koch-Henriksen N, Laursen B, Stenager E, Magyari M (2017) Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study. J Neurol Neurosurg Psychiatry 88:626–631. https://doi.org/10.1136/jnnp-2017-315907
doi: 10.1136/jnnp-2017-315907 pubmed: 28705951
Lunde HMB, Assmus J, Myhr KM et al (2017) Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry 88:621–625. https://doi.org/10.1136/jnnp-2016-315238
doi: 10.1136/jnnp-2016-315238 pubmed: 28365589
Martinelli V, Rodegher M, Moiola L, Comi G (2004) Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 25:S350–S355. https://doi.org/10.1007/s10072-004-0339-8
doi: 10.1007/s10072-004-0339-8 pubmed: 15727232
Bove R, Chitnis T (2013) Sexual disparities in the incidence and course of MS. Clin Immunol 149:201–210
doi: 10.1016/j.clim.2013.03.005
Polliack ML, Barak Y, Achiron A (2001) Late-onset multiple sclerosis. J Am Geriatr Soc 49:168–171. https://doi.org/10.1046/j.1532-5415.2001.49038.x
doi: 10.1046/j.1532-5415.2001.49038.x pubmed: 11207871
Peterson JW, Trapp BD (2005) Neuropathobiology of multiple sclerosis. Neurol Clin 23:107–129
doi: 10.1016/j.ncl.2004.09.008
Amato MP, Fonderico M, Portaccio E et al (2020) Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain 143:3013–3024. https://doi.org/10.1093/brain/awaa251
doi: 10.1093/brain/awaa251 pubmed: 32935843
Trojano M, Tintore M, Montalban X et al (2017) Treatment decisions in multiple sclerosis—insights from real-world observational studies. Nat Rev Neurol 13:105–118. https://doi.org/10.1038/nrneurol.2016.188
doi: 10.1038/nrneurol.2016.188 pubmed: 28084327
Magyari M, Joensen H, Laursen B, Koch-Henriksen N (2020) The Danish Multiple Sclerosis Registry. Brain Behav. https://doi.org/10.1002/brb3.1921
doi: 10.1002/brb3.1921 pubmed: 33128351 pmcid: 7821574
Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145:72–80. https://doi.org/10.1093/oxfordjournals.aje.a009034
doi: 10.1093/oxfordjournals.aje.a009034 pubmed: 8982025
Thiébaut ACM, Bénichou J (2004) Choice of time-scale in Cox’s model analysis of epidemiologic cohort data: a simulation study. Stat Med 23:3803–3820. https://doi.org/10.1002/sim.2098
doi: 10.1002/sim.2098 pubmed: 15580597
Noseworthy J, Paty D, Wonnacott T et al (1983) Multiple sclerosis after age 50. Neurology 33:1537–1544. https://doi.org/10.1212/wnl.33.12.1537
doi: 10.1212/wnl.33.12.1537 pubmed: 6606140
Bove RM, Healy B, Augustine A et al (2012) Effect of gender on late-onset multiple sclerosis. Mult Scler J 18:1472–1479. https://doi.org/10.1177/1352458512438236
doi: 10.1177/1352458512438236
Kister I, Chamot E, Cutter G et al (2012) Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci 318:94–99. https://doi.org/10.1016/j.jns.2012.03.017
doi: 10.1016/j.jns.2012.03.017 pubmed: 22507751
Ontaneda D (2019) Progressive multiple sclerosis. Contin Lifelong Learn Neurol 25:736–752. https://doi.org/10.1212/CON.0000000000000727
doi: 10.1212/CON.0000000000000727
Buron MD, Chalmer TA, Sellebjerg F et al (2020) Initial high-efficacy disease-modifying therapy in multiple sclerosis. Neurology 95:e1041–e1051. https://doi.org/10.1212/WNL.0000000000010135
doi: 10.1212/WNL.0000000000010135
Tremlett H, Zhao Y, Joseph J et al (2008) Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 79:1368–1374. https://doi.org/10.1136/jnnp.2008.145805
doi: 10.1136/jnnp.2008.145805 pubmed: 18535026
Alroughani R, Akhtar S, Ahmed S et al (2016) Is time to reach EDSS 6.0 faster in patients with late-onset versus young-onset multiple sclerosis? PLoS ONE. https://doi.org/10.1371/journal.pone.0165846
doi: 10.1371/journal.pone.0165846 pubmed: 27802328 pmcid: 5089776
Guillemin F, Baumann C, Epstein J et al (2017) Older age at multiple sclerosis onset is an independent factor of poor prognosis: a population-based cohort study. Neuroepidemiology 48:179–187. https://doi.org/10.1159/000479516
doi: 10.1159/000479516 pubmed: 28793296
Tremlett H, Devonshire V (2006) Is late-onset multiple sclerosis associated with a worse outcome? Neurology 67:954–959. https://doi.org/10.1212/01.wnl.0000237475.01655.9d
doi: 10.1212/01.wnl.0000237475.01655.9d pubmed: 17000960
Sormani MP, Tintorè M, Rovaris M et al (2008) Will Rogers phenomenon in multiple sclerosis. Ann Neurol 64:428–433. https://doi.org/10.1002/ana.21464
doi: 10.1002/ana.21464 pubmed: 18688811

Auteurs

Mads Albrecht Andersen (MA)

Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet Glostrup, Valdemar Hansens Vej 2, indgang 8, 2. sal, 2600, Glostrup, Denmark. mads.albrecht.andersen.01@regionh.dk.

Mathias Due Buron (MD)

Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet Glostrup, Valdemar Hansens Vej 2, indgang 8, 2. sal, 2600, Glostrup, Denmark.

Melinda Magyari (M)

Department of Neurology, Danish Multiple Sclerosis Center, Rigshospitalet Glostrup, Valdemar Hansens Vej 2, indgang 8, 2. sal, 2600, Glostrup, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH